Cloud-clone
SKU:MAA882Hu22
Monoclonal Antibody to Gastric Inhibitory Polypeptide (GIP)
Monoclonal Antibody to Gastric Inhibitory Polypeptide (GIP)
Couldn't load pickup availability
Immunocytochemistry: 5-20µg/mL;1:50-200
Optimal working dilutions must be determined by end user.
Product No.
MAA882Hu22
Organism Species
Homo sapiens (Human).
Source
Monoclonal antibody preparation
Host
Mouse
Potency (Clone Number)
A1
Ig Isotype
IgG2b Kappa
Purification
Protein A + Protein G affinity chromatography
Label
None
Immunogen
CPA882Hu21-OVA Conjugated Gastric Inhibitory Polypeptide (GIP)
Buffer Formulation
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Traits
Liquid
Concentration
1mg/ml
Organism Species More
n/a
Applications
WB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies.
UOM
20µl 100µl 200µl 1ml 10ml
SPECIFITY
The antibody is a mouse monoclonal antibody raised against GIP. It has been selected for its ability to recognize GIP in immunohistochemical staining and western blotting.
USAGE
Immunohistochemistry: 5-20µg/mL;1:50-200
Immunocytochemistry: 5-20µg/mL;1:50-200
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
| Magazine | Citations |
| Scientific Reports | The anti-hyperglycemic efficacy of a lipid-lowering drug Daming capsule and the underlyingsignaling mechanisms in a rat model of diabetes mellitus. pubmed:27721485 |
| Obesity surgery | The Effects of Duodenojejunal Omega Switch in Combination with High-Fat Diet and Control Diet on Incretins, Body Weight, and Glucose Tolerance in Sprague-Dawley Rats. pubmed:28840471 |
| Obesity Surgery | Preserving Duodenal-Jejunal (Foregut) Transit Does Not Impair Glucose Tolerance and Diabetes Remission Following Gastric Bypass in Type 2 Diabetes Sprague … Pubmed:29098544 |
| BioMed Research International | Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity |
| Diabetes Research and Clinical Practice | Low AS160 and high SGK basal phosphorylation associates with impaired incretin profile and type 2 diabetes in adipose tissue of obese patients Pubmed: 31734225 |
| OBESITY SURGERY | The Leading Role of Peptide Tyrosine Tyrosine in Glycemic Control After Roux-en-Y Gastric Bypass in Rats Pubmed: 31701411 |
| FUTURE SCIENCE | Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes Pubmed:35251693 |
Share
